FY2026 EPS Estimate for Spyglass Pharma Reduced by Analyst

Spyglass Pharma, Inc. (NASDAQ:SGP – Free Report) – Investment analysts at HC Wainwright cut their FY2026 EPS estimates for Spyglass Pharma in a report issued on Thursday, November 12th. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($2.76) per share for the year, down from their previous estimate of ($2.52). HC Wainwright currently has a “Buy” rating and a $43.00 target price on the stock. The consensus estimate for Spyglass Pharma’s current full-year earnings is ($2.77) per share. HC Wainwright also issued estimates for Spyglass Pharma’s Q4 2026 earnings at ($0.75) EPS, Q1 2027 earnings at ($0.69) EPS, Q3 2027 earnings at ($0.65) EPS, Q4 2027 earnings at ($0.66) EPS and FY2027 earnings at ($2.64) EPS.

Spyglass Pharma (NASDAQ:SGP – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.07).

A number of other analysts also recently issued reports on the company. UBS Group reiterated a “buy” rating on shares of Spyglass Pharma in a research report on Monday, October 5th. Stifel Nicolaus upped their price objective on shares of Spyglass Pharma from $42.00 to $44.00 and gave the stock a “buy” rating in a research report on Friday. Wall Street Zen upgraded shares of Spyglass Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. Weiss Ratings raised shares of Spyglass Pharma from a “sell (e)” rating to a “sell (d-)” rating in a research note on Friday. Finally, Citigroup lifted their target price on shares of Spyglass Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Friday. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $45.83.

Get Our Latest Research Report on Spyglass Pharma

Spyglass Pharma Stock Performance

Spyglass Pharma stock opened at $32.24 on Monday. The business has a 50-day simple moving average of $28.85 and a 200 day simple moving average of $24.87. Spyglass Pharma has a 52 week low of $17.06 and a 52 week high of $39.92.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in SGP. First Light Asset Management LLC bought a new stake in Spyglass Pharma during the first quarter worth about $9,716,000. Affinity Asset Advisors LLC purchased a new position in shares of Spyglass Pharma in the 1st quarter worth about $6,478,000. Monashee Investment Management LLC purchased a new position in shares of Spyglass Pharma in the 1st quarter worth about $2,461,000. Bank of America Corp DE purchased a new position in shares of Spyglass Pharma in the 1st quarter worth about $726,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Spyglass Pharma during the 2nd quarter valued at about $533,000.

Trending Headlines about Spyglass Pharma

Here are a few of the latest headlines about SGP:

  • Positive Sentiment: Spyglass Pharma’s price target was raised to $44, signaling improved potential upside in the analyst’s view. Spyglass Pharma price target raised to $44
  • Negative Sentiment: HC Wainwright lowered its earnings forecasts for several 2026 and 2027 periods, including FY2026 EPS to a loss of $2.76 from $2.52 and FY2027 EPS to a loss of $2.64 from $2.57. The firm nevertheless kept its Buy rating and $43 target.
  • Negative Sentiment: The company’s latest quarterly loss of $0.73 per share was wider than analysts’ $0.66 estimate, adding to concerns about near-term results.

Spyglass Pharma Company Profile

(Get Free Report)

SpyGlass Pharma is a clinical-stage ophthalmology company developing sustained-release drug delivery systems for chronic eye diseases. Its research is focused on reducing reliance on patients’ regular use of eye drops. The company’s lead program is a bimatoprost drug delivery system being developed to treat glaucoma and ocular hypertension. Bimatoprost is a medication used to lower eye pressure, and SpyGlass is studying a delivery approach intended to provide treatment over an extended period. SpyGlass Pharma’s work centers on advancing this ophthalmic delivery platform and its lead program through clinical development.

Recommended Stories

Earnings History and Estimates for Spyglass Pharma (NASDAQ:SGP)

Receive News & Ratings for Spyglass Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyglass Pharma and related companies with MarketBeat.com's FREE daily email newsletter.